Compare OOMA & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | LRMR |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.2M | 455.8M |
| IPO Year | 2015 | 2014 |
| Metric | OOMA | LRMR |
|---|---|---|
| Price | $17.75 | $3.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $18.77 | $16.50 |
| AVG Volume (30 Days) | 220.1K | ★ 1.3M |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 188.46 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $114,490,000.00 | N/A |
| Revenue This Year | $20.35 | N/A |
| Revenue Next Year | $4.17 | $1,816.14 |
| P/E Ratio | $71.00 | ★ N/A |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $9.79 | $1.73 |
| 52 Week High | $16.89 | $6.42 |
| Indicator | OOMA | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 80.02 | 31.12 |
| Support Level | $10.95 | $3.87 |
| Resistance Level | N/A | $4.18 |
| Average True Range (ATR) | 0.56 | 0.21 |
| MACD | 0.14 | -0.09 |
| Stochastic Oscillator | 98.71 | 6.31 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.